Scholarlink

<p>Immune checkpoint inhibitors (ICIs) are widely used in oncology. Approved ICIs work by blocking tumor-induced suppression of the immune response, allowing T&#xa0;cells to recognize and attack cancer cells. This immune activation can lead to specific side effects, making early detection and management essential. Screening helps identify these adverse events promptly. Depending on their severity, treatment may involve corticosteroids or targeted therapies. Typically, ICI therapy is paused for grade&#xa0;2 adverse events and higher, but it can often be resumed once the side effects have improved. In some cases, long-term treatment may be required, such as for patients who develop hypothyroidism.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nebenwirkungsmanagement bei Therapie mit Immuncheckpointinhibitoren

  • 期刊论文

  • 发表日期：

    2026年4月9日

查看全文
  • Christiane Leidinger,
  • Tanja Fehm,
  • Eugen Ruckhäberle,
  • Verena Friebe

摘要

Immune checkpoint inhibitors (ICIs) are widely used in oncology. Approved ICIs work by blocking tumor-induced suppression of the immune response, allowing T cells to recognize and attack cancer cells. This immune activation can lead to specific side effects, making early detection and management essential. Screening helps identify these adverse events promptly. Depending on their severity, treatment may involve corticosteroids or targeted therapies. Typically, ICI therapy is paused for grade 2 adverse events and higher, but it can often be resumed once the side effects have improved. In some cases, long-term treatment may be required, such as for patients who develop hypothyroidism.